Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice. 2002

Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd., 135, Komakado 1-chome, Gotemba-shi, Shizuoka 412-8513, Japan. miharamsh@chugai-pharm.co.jp

In the present study, we examined the effect of anti-IL-6 receptor antibody (MR16-1) on humoral and cellular immune responses in mice. MR16-1 did not affect antigen-specific antibody production in either the primary or secondary response in mice immunized with dinitro-phenyl (DNP)-keyhole limpet haemocyanin (KLH) in saline. DNP-KLH immunization with complete Freund's adjuvant (CFA) markedly augmented anti-DNP antibody production and induced interleukin 6 (IL-6) production in serum. In this case, MR16-1 significantly suppressed antibody production and further increased serum IL-6 levels. Regarding the cellular response, we studied the effect on the delayed-type hypersensitivity (DTH) response. DTH response was induced in mice by the immunization with Mycobacterium butyricum with incomplete Freund's adjuvant and following antigen challenge into the footpad 14 days after immunization. When MR16-1 was injected immediately after immunization, the DTH response was significantly suppressed and enlargement of the spleen was also suppressed. This suppressive effect was observed, when MR16-1 was administered on day 0, but not on days 5 and 10. Again, serum IL-6 levels were much higher in MR16-1-treated mice compared with controls. Furthermore, spleen cells from control mice released IL-2 and INFgamma by the stimulation of antigen in vitro. In contrast, spleen cells from MR16-1-treated mice produced these cytokines at a marginal level. In contrast, MR16-1 did not suppress the DTH response, when it was injected immediately after antigen challenge. Our results suggest that IL-6 does not always involve antibody production, although IL-6 augments antibody production, and that IL-6 is essential for the induction of Th1 cells.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D019947 Receptors, Interleukin-6 Cell surface receptors that are specific for INTERLEUKIN-6. They are present on T-LYMPHOCYTES, mitogen-activated B-LYMPHOCYTES, and peripheral MONOCYTES. The receptors are heterodimers of the INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT and the CYTOKINE RECEPTOR GP130. IL-6 Receptors,Interleukin-6 Receptor,Interleukin-6 Receptors,Receptors, IL-6,IL-6 Receptor,IL6 Receptor,IL6 Receptors,Interleukin 6 Receptor,IL 6 Receptor,IL 6 Receptors,Interleukin 6 Receptors,Receptor, IL-6,Receptor, IL6,Receptor, Interleukin 6,Receptor, Interleukin-6,Receptors, IL 6,Receptors, IL6,Receptors, Interleukin 6

Related Publications

Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
March 2013, Transplant immunology,
Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
December 2014, Transplantation,
Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
October 2017, Biochemistry. Biokhimiia,
Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
March 2018, Cellular and molecular neurobiology,
Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
January 2003, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
January 2015, International immunology,
Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
December 2006, Endocrine, metabolic & immune disorders drug targets,
Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
November 2000, Annals of the rheumatic diseases,
Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
November 2013, Experimental and therapeutic medicine,
Masahiko Mihara, and Norihiro Nishimoto, and Kazuyuki Yoshizaki, and Takashi Suzuki
December 2002, Cytokine,
Copied contents to your clipboard!